12.12.2012 • NewsgeneticsPeopleinvestments

Russian Billionaire Invests in US Genetics Company 23andMe

Russian billionaire Yuri Milner, best-known for investments linking consumers to the Internet, is placing a bet on genetics.

Milner, who backed companies ranging from Facebook to gaming company Zynga, has led a $50 million funding round into 23andMe, a Mountain View, California, company that helps people decipher their genetic makeup.

His investment could shine a spotlight on biotechnology startups, which have taken a backseat in visibility to sectors like cloud computing and Internet services targeted at consumers.

23andMe, named for the 23 pairs of chromosomes that make up each person's genome, also announced a price drop for its saliva-based test, to $99 from $299.

For that price, consumers learn specifics about ancestry and genetic traits, including the possible conditions and diseases to which they may have a genetic propensity.

Existing investors joining the funding round include Anne Wojcicki, 23andMe's chief executive; Sergey Brin, Wojcicki's husband and co-founder of Google; New Enterprise Associates; Google Ventures; and MPM Capital.

The company's last funding round was about $31 million, raised two years ago. Since its founding in 2006, 23andMe has raised about $68 million.

Biotechnology has fostered some hefty investment exits recently. On Monday, Amgen said it would pay $415 million for Iceland-based Decode Genetics.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.